Skip to main content

Main menu

  • HOME
  • LATEST ARTICLES
  • ALL ISSUES
  • AUTHORS & REVIEWERS
  • RESOURCES
    • About BJGP Open
    • BJGP Open Accessibility Statement
    • Editorial Board
    • Editorial Fellowships
    • Audio Abstracts
    • eLetters
    • Alerts
    • BJGP Life
    • Research into Publication Science
    • Advertising
    • Contact
  • SPECIAL ISSUES
    • Artificial Intelligence in Primary Care: call for articles
    • Social Care Integration with Primary Care: call for articles
    • Special issue: Telehealth
    • Special issue: Race and Racism in Primary Care
    • Special issue: COVID-19 and Primary Care
    • Past research calls
    • Top 10 Research Articles of the Year
  • BJGP CONFERENCE →
  • RCGP
    • British Journal of General Practice
    • BJGP for RCGP members
    • RCGP eLearning
    • InnovAIT Journal
    • Jobs and careers

User menu

  • Alerts

Search

  • Advanced search
Intended for Healthcare Professionals
BJGP Open
  • RCGP
    • British Journal of General Practice
    • BJGP for RCGP members
    • RCGP eLearning
    • InnovAIT Journal
    • Jobs and careers
  • Subscriptions
  • Alerts
  • Log in
  • Follow BJGP Open on Instagram
  • Visit bjgp open on Bluesky
  • Blog
Intended for Healthcare Professionals
BJGP Open

Advanced Search

  • HOME
  • LATEST ARTICLES
  • ALL ISSUES
  • AUTHORS & REVIEWERS
  • RESOURCES
    • About BJGP Open
    • BJGP Open Accessibility Statement
    • Editorial Board
    • Editorial Fellowships
    • Audio Abstracts
    • eLetters
    • Alerts
    • BJGP Life
    • Research into Publication Science
    • Advertising
    • Contact
  • SPECIAL ISSUES
    • Artificial Intelligence in Primary Care: call for articles
    • Social Care Integration with Primary Care: call for articles
    • Special issue: Telehealth
    • Special issue: Race and Racism in Primary Care
    • Special issue: COVID-19 and Primary Care
    • Past research calls
    • Top 10 Research Articles of the Year
  • BJGP CONFERENCE →
Research

Should azithromycin be used to treat COVID-19? A rapid review

Kome Gbinigie and Kerstin Frie
BJGP Open 2020; 4 (2): bjgpopen20X101094. DOI: https://doi.org/10.3399/bjgpopen20X101094
Kome Gbinigie
1 GP and DPhil Student, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Oghenekome.gbinigie@phc.ox.ac.uk
Kerstin Frie
2 Post-Doctoral Researcher, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kerstin Frie
  • Article
  • Figures & Data
  • Info
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1. Flowchart showing the process for identification of studies suitable for inclusion

Tables

  • Figures
    • View popup
    Table 1. Summary of characteristics of identified in vivo study
    Authors (Year)CountrySettingSample size (treatment/control)Mean age (SD)Inclusion criteriaTreatmentPrimaryoutcomeFindings
    Gautret et al (2020)FranceHospitals in Marseille, Nice, Avignon and Briançon6 – AZT and HCQ14 – HCQ alone16 – controlTreatment groups: 51.2 (18.7)Control: 37.3 (24.0)
    • SARS-CoV-2 carriage in nasopharyngeal sample

    • Age>12 years (treatment groups only)

    Six patients received 500 mg AZT on Day 1 then 250 mg daily for four days and200 mg HCQ three times a day for 10 days.14 patients received 200 mg HCQ three times a day for 10 days.Outcome of a nasopharyngeal swab on Day 6Virological cure:AZT and HCQ – 100%HCQ alone – 57.1%Controls – 12.5% p<0.001
    • AZT = azithromycin; HCQ = hydroxychloroquine.

    • View popup
    Table 2. Risk of bias assessment for the included in vivo study
    BiasRapid review authors’ judgmentReason for judgment
    Random sequence generationHigh riskNon-randomised trial
    Allocation concealmentHigh riskOpen-label
    BlindingHigh riskOpen-label
    Incomplete outcome dataHigh riskIntention-to-treat analysis not performed
    Selective reportingUnclear riskNo adverse event data reported, although the authors state that this will be reported separately at the end of the trial
    Other biasHigh riskUnder-powered according to the authors’ own power calculation

Supplementary Data

SUPPLEMENTARY MATERIALS

  • bjgpopen20X101094_Supp.pdf -

    Supplementary material is not copyedited or typeset, and is published as supplied by the author(s). The author(s) retain(s) responsibility for its accuracy.

Back to top
Previous ArticleNext Article

In this issue

BJGP Open
Vol. 4, Issue 2
June 2020
  • Table of Contents
  • Index by author
Download PDF
Download PowerPoint
Email Article

Thank you for recommending BJGP Open.

NOTE: We only request your email address so that the person to whom you are recommending the page knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Should azithromycin be used to treat COVID-19? A rapid review
(Your Name) has forwarded a page to you from BJGP Open
(Your Name) thought you would like to see this page from BJGP Open.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Should azithromycin be used to treat COVID-19? A rapid review
Kome Gbinigie, Kerstin Frie
BJGP Open 2020; 4 (2): bjgpopen20X101094. DOI: 10.3399/bjgpopen20X101094

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Should azithromycin be used to treat COVID-19? A rapid review
Kome Gbinigie, Kerstin Frie
BJGP Open 2020; 4 (2): bjgpopen20X101094. DOI: 10.3399/bjgpopen20X101094
del.icio.us logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
  • Mendeley logo Mendeley

Jump to section

  • Top
  • Article
    • Abstract
    • How this fits in
    • Introduction
    • Method
    • Results
    • Discussion
    • Strengths and limitations
    • Notes
    • References
  • Figures & Data
  • Info
  • eLetters
  • PDF

Keywords

  • COVID-19
  • Azithromycin
  • anti-bacterial agents
  • primary health care
  • general practice

More in this TOC Section

  • How does decontextualised risk information affect clinicians understanding of risk and uncertainty in primary care diagnosis? A qualitative study of clinical vignettes
  • Declining number of home visits to older adults by GPs: an observational study using data from electronic health records in The Netherlands, 2017–2023
  • What’s been tried: a curated catalogue of efforts to improve access to general practice
Show more Research

Related Articles

Cited By...

Intended for Healthcare Professionals

 
 

British Journal of General Practice

NAVIGATE

  • Home
  • Latest articles
  • Authors & reviewers
  • Accessibility statement

RCGP

  • British Journal of General Practice
  • BJGP for RCGP members
  • RCGP eLearning
  • InnovAiT Journal
  • Jobs and careers

MY ACCOUNT

  • RCGP members' login
  • Terms and conditions

NEWS AND UPDATES

  • About BJGP Open
  • Alerts
  • RSS feeds
  • Facebook
  • Twitter

AUTHORS & REVIEWERS

  • Submit an article
  • Writing for BJGP Open: research
  • Writing for BJGP Open: practice & policy
  • BJGP Open editorial process & policies
  • BJGP Open ethical guidelines
  • Peer review for BJGP Open

CUSTOMER SERVICES

  • Advertising
  • Open access licence

CONTRIBUTE

  • BJGP Life
  • eLetters
  • Feedback

CONTACT US

BJGP Open Journal Office
RCGP
30 Euston Square
London NW1 2FB
Tel: +44 (0)20 3188 7400
Email: bjgpopen@rcgp.org.uk

BJGP Open is an editorially-independent publication of the Royal College of General Practitioners

© 2025 BJGP Open

Online ISSN: 2398-3795